Brand | Exbio |
Product type | Primary antibodies |
Reactivity | Human, Porcine |
Clonality | Monoclonal |
Brand: | Exbio |
Product no.: | 11-453-C025 |
Product type: | Primary antibodies |
Host species: | Mouse |
Product name: | Mouse Monoclonal to CD105 / Endoglin |
Antigen: | CD105 |
Clonality: | Monoclonal |
Negative species: | Canine (Dog), Equine (Horse) |
Clone: | MEM-229 |
Isotype: | IgG2a |
Immunogen: | Recombinant Vaccinia virus containing the human CD105 (L-isoform) cDNA. |
Format: | purified |
Specificity: | The antibody MEM-229 recognizes CD105 (Endoglin), a 90 kDa type I integral membrane homodimer glycoprotein expressed on vascular endothelial cells (small and large vessels), activated monocytes and tissue macrophages, stromal cells of certain tissues including bone marrow, pre-B lymphocytes in fetal marrow and erythroid precursors in fetal and adult bone marrow; it is also present on syncytiotrophoblast on placenta throughout pregnancy. _x000D_ |
Categories: | CD Antigens & MHC (Veterinary), CD and Related Antigens (Human) |
Concentration: | 1 mg/ml |
Storage buffer: | Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4 |
Storage / stability: | Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label. |
Background: | CD105 (Endoglin) is a homodimeric transmembrane glycoprotein serving in presence of TGFbetaR-2 as a receptor for TGFbeta-1 and TGFbeta-3. CD105 is highly expressed on endothelial cells and promotes angiogenesis during wound healing, infarcts and in a wide range of tumours and its gene expression is stimulated by hypoxia. CD105 prevents apoptosis in hypoxic endothelial cells and also antagonises the inhibitory effects of TGFbeta-1 on vascular endothelial cell growth and migration. Normal cellular levels of CD105 are required for formation of new blood vessels. |
Purity: | > 95% (by SDS-PAGE) |
Purification: | Purified by protein-A affinity chromatography |
Product specific references: | *Plánka L, Necas A, Srnec R, Rauser P, Starý D, Jancár J, Amler E, Filová E, Hlucilová J, Kren L, Gál P: Use of allogenic stem cells for the prevention of bone bridge formation in_x000D_ miniature pigs. Physiol Res. 2009;58(6):885-93. |
General references: | *Piao M, Tokunaga O: Significant expression of endoglin (CD105), TGFbeta-1 and TGFbeta R-2 in the_x000D_ atherosclerotic aorta: an immunohistological study. J Atheroscler Thromb. 2006 Apr;13(2):82-9._x000D_ , *Warrington K, Hillarby MC, Li C, Letarte M, Kumar S: Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells. Anticancer Res. 2005 May-Jun;25(3B):1851-64._x000D_ , *Guo B, Slevin M, Li C, Parameshwar S, Liu D, Kumar P, Bernabeu C, Kumar S: CD105 inhibits transforming growth factor-beta-Smad3 signalling. Anticancer Res. 2004 May-Jun;24(3a):1337-45._x000D_ , *Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, Bernabeu C, Kumar S: CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci. 2003 Jul 1;116(Pt 13):2677-85._x000D_ _x000D_ , *Zhu Y, Sun Y, Xie L, Jin K, Sheibani N, Greenberg DA: Hypoxic induction of endoglin via mitogen-activated protein kinases in mouse brain microvascular endothelial cells. Stroke. 2003 Oct;34(10):2483-8._x000D_ _x000D_ |
Related products: | - Mouse Monoclonal to CD107b / LAMP-2 - Mouse Monoclonal to CD106 / VCAM-1 - Mouse Monoclonal to CD107a / LAMP-1 |
Shipping condition: | Room temperature |